Talus Bio provides a proprietary platform that quantifies and modulates the regulome—the network of regulatory proteins that control gene expression—directly in live cells using functional proteomics and high‑throughput assays. The system generates millions of compound‑target interaction data points and leverages AI to design chemical libraries that target transcription factors, cofactors, and splicing regulators, enabling pharmaceutical companies to discover and develop therapies against previously undruggable regulatory proteins.
Funding
$11.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
BVFC+2Founders
Product
Problem
The regulatory genome (regulome) that controls gene expression is difficult to study in its native cellular context, leaving many potential drug targets, such as transcription factors and splicing regulators, inaccessible to traditional discovery methods.
Solution
Talus Bio offers a proprietary platform that quantifies and modulates the regulome directly in live cells using functional proteomics and high‑throughput cell‑based assays. The system generates tens of millions of compound‑target interaction data points per month, enabling the identification of druggable sites within transcription factors, cofactors, and splicing regulators. AI‑driven chemical library design creates compounds specifically aimed at these regulatory proteins. The platform supports a full discovery pipeline—from target identification through hit‑to‑lead, lead optimization, and IND‑enabling—focused on oncology, rare diseases, and immune disorders.
Target Audience
Primary customers are pharmaceutical and biotechnology companies seeking to expand their target space into regulatory proteins for disease‑modifying therapies.
Features
- Live‑cell functional proteomics that quantifies thousands of regulome targets in their native nuclear environment
- High‑throughput assay infrastructure producing tens of millions of compound‑target interaction data points monthly
- AI‑generated chemical libraries tailored to modulate transcription factors, cofactors, and splicing regulators
- End‑to‑end discovery workflow covering target validation, hit discovery, hit‑to‑lead, lead optimization, and IND‑enabling
- Focused pipelines for first‑in‑class programs targeting previously undruggable regulators in oncology, rare disease, and immunology